SCHEMBL30731915

SCHEMBL30731915

C[C@@H]1CN(C(=O)OC(C)(C)C)[C@@H](C)CN1CC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.50
▸ PDK2 Q15119 1/20 0.50
▸ PDK3 Q15120 1/20 0.50
▸ PDK4 Q16654 1/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HTT P42858 1/20 0.48
▸ CYP2C19 P33261 1/20 0.47
▸ GRIN2B Q13224 6/20 0.46
▸ CYP2D6 P10635 3/20 0.46
▸ CYP2C9 P11712 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ PARP1 P09874 1/20 0.45
▸ YAP1 P46937 2/20 0.44
▸ CYP3A4 P08684 2/20 0.43
▸ STS P08842 1/20 0.43
▸ FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30781698 1.00 PDK1 (0.50) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL26924699 0.89 SMN1; SMN2 (0.54) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL27140654 0.89 SMN1; SMN2 (0.54) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30706191 0.87 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL26927558 0.87 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30706025 0.87 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30731906 0.87 PDK1 (0.51) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30732153 0.86 PDK1 (0.52) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30731961 0.86 PDK1 (0.52) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL30781746 0.84 PDK1 (0.52) PDK1PDK2PDK3PDK4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 — — CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR PDK1 3958/4885PDK2 3515/4885PDK3 3377/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR PDK1 3958/4885PDK2 3515/4885PDK3 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback